Image 7_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.tiff by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Table 1_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.docx by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Image 4_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.tiff by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Image 3_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.tiff by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Image 2_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.tiff by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Image 5_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.tiff by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Image 6_Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.tif by Minyong Choi (22465405)

“…Furthermore, among the inconsistent blood draw timing and analytical methods, we aimed to suggest the most suitable strategies in the clinical setting.…”

Supplementary file 1_Association of antenatal dexamethasone administration timing with outcomes in preterm infants in a low- and middle-income country.docx by Vijay Kalrao (22696397)

“…No other secondary outcomes differed significantly.</p>Conclusion<p>Dexamethasone administration within 24 h before delivery did not reduce mortality but significantly decreased the risk of severe NEC. …”

Image 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.jpeg by Shuangmei Zhang (1807303)

“…Th17 cell frequency and IL-17 levels decreased by 68 and 84.47%, respectively. Strong baseline correlations were observed between IL-17, Th17, and clinical scores (r = 0.642–0.970, p < 0.001), with progressive uncoupling of these relationships during treatment. …”

Table 1_Mitochondrial oxygen metabolism as a potential predictor of weight loss after laparoscopic sleeve gastrectomy for class III obesity.xlsx by Markus Engelmann (20516393)

“…They showed a significant weight loss and a decrease in relative fat mass after six months. …”

Data Sheet 1_Hyperbaric oxygen therapy for radiation enteritis and clinical parameters: a systematic review and meta-analysis.docx by Yuhan Wang (595964)

“…</p>Results<p>This study analyzed data from 22 clinical studies involving 1,318 subjects, including six RCTs incorporated into a meta-analysis. Moderate-quality evidence suggested that HBOT could significantly reduce the incidence of RE [OR = 0.32, 95% CI (0.14, 0.72), P = 0.006], particularly showing a significant advantage in decreasing the incidence of grade 3 or higher RE according to the RTOG/EORTC criteria [OR = 0.37, 95% CI (0.17, 0.82), P = 0.01]. …”

Supplementary file 1_Effects of non-HDL-C and statin therapy on mortality in ARDS: a retrospective cohort study.docx by Haiming Hu (12451365)

“…Both univariate (HR, 0.48; 95% CI, 0.41–0.58; p < 0.001) and multivariate (HR, 0.49; 95% CI, 0.41–0.58; p < 0.001) Cox regression analyses revealed that statin therapy significantly decreased short-term mortality. Subsequent subgroup analyses further indicated that the beneficial effect of statins was more evident in patients with elevated non-HDL-C levels.…”

Supplementary file 2_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38–1.11). …”

Supplementary file 1_The efficacy of resveratrol in the treatment of liver fibrosis: a systematic review and meta-analysis of preclinical studies.docx by Dehua Luo (22275916)

“…</p>Results<p>Resveratrol markedly attenuated collagen deposition and reduced hydroxyproline levels, a central marker of fibrotic progression. It significantly inhibited the accumulation of extracellular matrix components and modulated profibrotic mediators. …”

Supplementary file 5_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38–1.11). …”

Supplementary file 3_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38–1.11). …”

Supplementary file 1_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38–1.11). …”

Supplementary file 4_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38–1.11). …”

Supplementary file 6_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38–1.11). …”

Figure 3 from A Cost-Effective Two-Step Approach for Multi-Cancer Early Detection in High-Risk Populations by Shuaipeng Geng (20612220)